334 related articles for article (PubMed ID: 17412430)
21. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Valent P
Br J Haematol; 2008 Jul; 142(3):361-78. PubMed ID: 18540942
[TBL] [Abstract][Full Text] [Related]
22. The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Alvarez RH; Kantarjian H; Cortes JE
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S4-14. PubMed ID: 17292736
[TBL] [Abstract][Full Text] [Related]
23. Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.
Hui CH; Hughes TP
Clin Adv Hematol Oncol; 2003 Sep; 1(9):538-45, 559. PubMed ID: 16258446
[TBL] [Abstract][Full Text] [Related]
24. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
25. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Kang HY; Hwang JY; Kim SH; Goh HG; Kim M; Kim DW
Haematologica; 2006 May; 91(5):659-62. PubMed ID: 16627254
[TBL] [Abstract][Full Text] [Related]
26. Imatinib alone and in combination for chronic myeloid leukemia.
Druker BJ
Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
[TBL] [Abstract][Full Text] [Related]
27. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
28. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
Stein AM; Bottino D; Modur V; Branford S; Kaeda J; Goldman JM; Hughes TP; Radich JP; Hochhaus A
Clin Cancer Res; 2011 Nov; 17(21):6812-21. PubMed ID: 21903771
[TBL] [Abstract][Full Text] [Related]
29. Roots of imatinib resistance: a question of self-renewal?
Burchert A
Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
[TBL] [Abstract][Full Text] [Related]
30. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
31. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
32. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
[TBL] [Abstract][Full Text] [Related]
33. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Miething C; Grundler R; Mugler C; Brero S; Hoepfl J; Geigl J; Speicher MR; Ottmann O; Peschel C; Duyster J
Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4594-9. PubMed ID: 17360569
[TBL] [Abstract][Full Text] [Related]
34. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
35. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
36. Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
Amiel A; Yukla M; Gaber E; Leopold L; Josef G; Fejgin M; Lishner M
Cancer Genet Cytogenet; 2006 Jul; 168(2):120-3. PubMed ID: 16843101
[TBL] [Abstract][Full Text] [Related]
37. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
38. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
[No Abstract] [Full Text] [Related]
39. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
Breccia M; Frustaci AM; Cannella L; Soverini S; Stefanizzi C; Federico V; Grammatico S; Santopietro M; Alimena G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):195-7. PubMed ID: 19156415
[TBL] [Abstract][Full Text] [Related]
40. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]